It’s almost impossible to read an article, have a discussion, or even watch celebrity news without the topic of GLP-1s coming up. While a significant benefit to diabetes patients, what makes GLP-1s a true game-changing drug class is their potential to have meaningful impact on the treatment of other disease areas beyond diabetes, including obesity and obesity-related complications/comorbidities (e.g., sleep apnea, osteoarthritis, cardiovascular disease, chronic kidney disease).

Our key finding at this stage is that typically GLP-1s are likely to be complementary to existing standard of care vs. displacing in nature. While GLP-1 impact across conditions/procedures is likely to vary, we view GLP-1s as a friend (or perhaps a frenemy) for most Medtechs vs. a foe. As we discuss in this report, the headwinds affecting GLP-1s are very real and even if fully addressed, GLP-1s are unlikely to meet the needs of all eligible patients. Hence, we believe Medtechs and GLP-1s both have a multitude of upsides to pursue, some even in partnership with each other.

To learn more, please download our analysis.

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2023 L.E.K. Consulting LLC 

How Hospitals Can Use Software to Drive Strategic Supply Chain Transformation
healthcare workers in meeting
Here are four key industry areas where timely action can help hospitals mitigate issues with their supply chain.

Related Insights